No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Clinical benefit seen with ibrutinib for relapsed/refractory multiple mantle cell lymphoma in a real-world population

byKathleen Lau

March 11, 2021

in StudyGraphics

#VisualAbstract: Circulating tumor DNA levels may predict treatment response in patients with advanced melanoma

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

Hematology

FDA grants priority review for iberdomide-based myeloma regimen

March 6, 2026

Reduced gestational weight gain with lifestyle intervention

Cardiology

Replacing sedentary time with physical activity may lower risk of all-cause mortality

March 2, 2026

AI Roundup

Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy

February 20, 2026

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Weekly Rewinds

2 Minute Medicine Rewind February 16, 2026

February 16, 2026

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

Screening plus Eave Tubes provides a cost-effective strategy to alleviate burden of malaria in Côte d’Ivoire

Epidemiologic features of the 2018-2019 measles outbreak in New York City

Study details societal costs of a measles outbreak

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Resuming oral anticoagulant (OAC) therapy after an OAC-related bleed associated with higher rates of bleeding

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports